Fluidigm Corporation (NASDAQ:FLDM) Files An 8-K Entry into a Material Definitive Agreement

On April 21, 2020, Fluidigm Corporation (the “Company”) and Silicon Valley Bank (“SVB”) entered into the Third Amendment to Loan and Security Agreement (the “Amendment”), which amends the Loan and Security Agreement dated as of August 2, 2018, between the Company and SVB (as amended by the Default Waiver and First Amendment to Loan and Security Agreement dated September 7, 2018, and the Second Amendment to Loan and Security Agreement dated November 20, 2019, the “Loan Agreement”).

The Amendment extends the maturity date of the Loan Agreement by two years, to August 2, 2022 and amends the interest rate to be the greater of (i) prime rate (as customarily defined), plus 0.50%, floating, and (ii) 5.25%. The Amendment also includes various administrative changes.

No amounts are outstanding under the Loan Agreement, as amended, as of the date of this report.

The foregoing description of the Amendment is qualified in its entirety by reference to the Amendment attached as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.

Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

The information set forth under Item 1.01 is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

FLUIDIGM CORP Exhibit
EX-10.1 2 exhibit101svbloanamend3.htm EXHIBIT 10.1 Exhibit Exhibit 10.1THIRD AMENDMENTTOLOAN AND SECURITY AGREEMENTThis Third Amendment to Loan and Security Agreement (this “Amendment”) is entered into this 21st day of April,…
To view the full exhibit click here

About Fluidigm Corporation (NASDAQ:FLDM)

Fluidigm Corporation creates, manufactures and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company’s core microfluidics and mass cytometry technologies. The Company operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment. Its products include preparatory instruments, preparatory analytical instruments, analytical instruments, integrated fluidic circuits (IFCs), and assays and reagents. Its preparatory instruments include C1 Single-Cell Auto Prep System, Access Array System, Juno System and IFCs, and Callisto System and IFC. Its analytical instruments include Biomark HD System, EP1 System and Helios/CyTOF 2 System. Its assays and reagents include Delta Gene and SNP Type Assays, and Access Array Target-Specific Primers and Targeted Sequencing Prep Primers.